Printer Friendly

IGI ANNOUNCES EFFECTIVENESS OF REGISTRATION STATEMENT

 IGI ANNOUNCES EFFECTIVENESS OF REGISTRATION STATEMENT
 BUENA, N.J., May 29 /PRNewswire/ -- IGI, Inc. (AMEX: IG) announced


today that the Securities and Exchange Commission has declared effective its registration statement relating to the offering of 364,955 shares of common stock held by certain shareholders.
 The shares being registered were sold in a private placement in January 1992. A prospectus relating to the shares may be obtained from IGI, Inc., Wheat Road and Lincoln Avenue, P.O. Box 687, Buena, N.J., 08310, Attention: Treasurer.
 IGI, headquartered in Buena, has development programs in pharmaceuticals, vaccines, cosmetics, consumer and industrial products based on a Novasome(TM) lipid vesicle encapsulation technology developed by its majority-owned subsidiary, Micro Vesicular Systems, Inc.
 Novasome is a trademark of a subsidiary of IGI, Inc.
 -0- 5/29/92
 /CONTACT: Michael Dodge of IGI, 609-697-1441, or Thomas Redington, of Redington, Inc., 203-222-7399, or 212-926-1733, for IGI/
 (IG) CO: IGI, Inc. ST: New Jersey IN: MTC SU:


CK-TS -- NY022 -- 5120 05/29/92 10:38 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 29, 1992
Words:168
Previous Article:GAMMA BIOLOGICALS REPORTS INCREASED SALES FOR FISCAL YEAR ENDED MARCH 31, 1992
Next Article:KAISER'S DAVID LAWRENCE ADDRESSES NATIONAL HEALTH CARE REFORM AT NATIONAL LABOR MANAGEMENT CONFERENCE
Topics:


Related Articles
IGI FIRST QUARTER REVENUE UP 7 PERCENT: ADVANCES CITED IN COSMETIC, VACCINE, PHARMACEUTICAL DEVELOPMENTS
IGI ANNOUNCES SPINOFF FILING WITH SEC
SEC DECLARES NOVAVAX REGISTRATION STATEMENT EFFECTIVE
IGI and Johnson & Johnson Medical Sign Licensing Agreement.
IGI Seeks New Distributor For Dermatological Products.
IGI in Loan Extension With Its Banks.
IGI Granted New Vaccine License.
IGI and Fujisawa Pharmaceutical to Collaborate on Developing Proprietary Dermatological Products.
IGI and Fujisawa Pharmaceutical to Collaborate On Developing Proprietary Dermatological Products.
IGI Acquires Rights to Flashtab(TM) Delivery Technology For Use with Acetaminophen.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters